Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07609225 · ClinicalTrials.gov registry record · Early Phase 1
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT07609225: Clinical Trial Early Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT07609225 is a Early Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 15 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07609225, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if CSE-MRI is as accurate as FLT PET in telling the difference between active and inactive marrow. The best way to do the comparison between the two imaging procedures is if they are done at the same time on the same patient. This is possible with use of a scanner at the University of Wisconsin Hospitals and Clinics (UW Health), the GE SIGNA PET/MR scanner. The prediction is that CSE-MRI as accurate as FLT at telling the difference between active and inactive marrow in patients with metastatic prostate cancer, and that is the primary reason for this study. 15 participants will be enrolled and on study for up to 14 months.
Primary Outcome
The mean Dice similarity coefficient (DSC) between active bone marrow volumes derived from CSE-MRI and ¹⁸F-FLT PET across all enrolled patients. A mean DSC of ≥0.7 will indicate that CSE-MRI is a clinically acceptable alternative to FLT PET for identifying ABM
Interventions
- DRUG 3'-Deoxy-3'-[18F]-fluorothymidine
- DEVICE Chemical-shift-encoded MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-07 |
| Phase | Early Phase 1 |
What is known before NCT07609225 opens enrollment
NCT07609225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which 3'-Deoxy-3'-[18F]-fluorothymidine is the first listed.
NCT07609225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07609225 about?
NCT07609225 is a clinical study titled "Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy". This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if C...
What is the current status of trial NCT07609225?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2026-07. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07609225?
The interventions under investigation include: 3'-Deoxy-3'-[18F]-fluorothymidine (DRUG), Chemical-shift-encoded MRI (DEVICE).
Who is sponsoring clinical trial NCT07609225?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07609225's enrollment target sits among peer trials
15 1403rd of 2000 higher than 527 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia